GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Durect Corp (NAS:DRRX) » Definitions » Earnings Yield %

Durect (Durect) Earnings Yield % : N/A% (As of Apr. 28, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Durect Earnings Yield %?

The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

As of today (2024-04-28), the stock price of Durect is $0.9313. Durect's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.25. Therefore, Durect's earnings yield of today is N/A%.

The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Durect's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Durect Earnings Yield % Calculation

Earnings yield is the reciprocal of the P/E Ratio.

Durect's Earnings Yield for today is calculated as

Earnings Yield=Earnings per Share (Diluted) (TTM)/Share Price
=-1.250/0.9313
=N/A %

Durect's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.250 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Earnings Yield=Net Income /Market Cap

The earnings in the calculation is the Trailing Twelve Months earnings.


Durect  (NAS:DRRX) Earnings Yield % Explanation

If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.

Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.

Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %.

Be Aware

Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.


Durect Earnings Yield % Related Terms

Thank you for viewing the detailed overview of Durect's Earnings Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Durect (Durect) Business Description

Traded in Other Exchanges
Address
10260 Bubb Road, Cupertino, CA, USA, 95014
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
Executives
Judith J. Robertson director 10260 BUBB ROAD, CUPERTINO CA 95014
Gail J Maderis director 364 LOMBARD ST., SAN FRANCISCO CA 94133
Timothy M. Papp officer: Chief Financial Officer C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO CA 95014
Gail M Farfel director 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Mohammad Azab director C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Peter S Garcia director ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Norman Sussman officer: Chief Medical Officer C/O DURECT CORP., 10260 BUBB ROAD, CUPERTINO CA 95014
Bleichroeder Lp 10 percent owner 1345 AVENUE OF THE AMERICAS, 47TH FLOOR, NEW YORK NY 10105
Judy R Joice officer: Sr. VP Operations & Corp QA 10260 BUBB ROAD, CUPERTINO CA 95014
21 April Fund Lp 10 percent owner 1345 AVENUE OF THE AMERICAS, 47TH FLOOR, New York NY 10105
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Michael Arenberg officer: Chief Financial Officer 10260 BUBB ROAD, CUPERTINO CA 95014
James E Brown director, officer: President & CEO 10240 BUBB RD, CUPERTINO CA 95014
First Eagle Investment Management, Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105